Beyond Tumor Tissue ADC Trials: Exploring ctDNA Dynamics & Multiomic Approaches for Faster Development Decisions - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Beyond Tumor Tissue ADC Trials: Exploring ctDNA Dynamics & Multiomic Approaches for Faster Development Decisions

11:30 am - Wednesday 14th October 2026

Contextualizing the importance of biomarker and multiomic approaches to inform early ADC clinical development
Understanding how ctDNA dynamics can provide an early, quantitative molecular response readout to inform program ADC Go/No-Go decisions and dose or cohort expansion selection
Seeing how multiomic approaches and epigenomic signatures in blood can be used to assign tumor subtype and identify subtype transformation

Speakers:

Jean-Francois Martini

Jean-Francois Martini

Senior Director, Translational Strategy & Applications

Guardant Health